bHLH and bHLHZip are highly conserved structural domains mediating DNA binding and speci®c proteinprotein interactions. They are present in a family of transcription factors, acting as dimers, and their selective dimerization is utilized to switch on and o cell proliferation, dierentiation or apoptosis. Myc is a bHLHZip protein involved in growth control and cancer, which operates in a network with the structurally related proteins Max, Mad and Mnt. It does not form homodimers, working as a heterodimer with Max; Max, instead, forms homodimers and heterodimers with Mad and Mnt. Myc/Max dimers activate gene transcription, while Mad/Max and Mnt/Max complexes are Myc/Max antagonists and act as repressors. Modifying the molecular recognition of dimers may provide a tool for interfering with Myc function and, in general, for directing the molecular switches operated via bHLH(Zip) proteins. By molecular modelling and mutagenesis, we analysed the contribution of single amino acids to the molecular recognition of Myc, creating bHLHZip domains with altered dimerization speci®city. We report that Myc recognition speci®city is encoded in a short region within the leucine zipper; mutation of four amino acids generates a protein, Omomyc, that homodimerizes eciently and can still heterodimerize with wild type Myc and Max. Omomyc sequestered Myc in complexes with low DNA binding eciency, preventing binding to Max and inhibiting Myc transcriptional activator function. Consistently with these results, Omomyc produced a proliferation arrest in NIH3T3 cells. These data demonstrate the feasibility of interfering with fundamental biological processes, such as proliferation, by modifying the dimerization selectivity of a bHLHZip protein; this may facilitate the design of peptides of potential pharmacological interest.
Introduction
The Max network is a cellular regulatory circuit, involved in cell fate determination (Amati and Land, 1994; Henriksson and Luscher, 1996) . The circuit is operated by dimers of the bHLHZip (basic helix ± loop ± helix/zipper) proteins Myc, Max, Mad (Mad1, Mxi or Mad2, Mad3, Mad4), Mnt (Rox); Max holds a central position, participating in the formation of a variety of protein complexes which bind DNA and regulate gene transcription. Myc/Max dimers induce proliferation or apoptosis, while Max/Mad and Max/ Mnt complexes cause cell growth arrest and differentiation (Amati et al., 1992; Evan et al., 1992; Hurlin et al., 1995 Hurlin et al., , 1997 Meroni et al., 1997; Zervos et al., 1993) . All dimers recognize in vitro the same consensus binding site, the CACGTG E-box, but have distinct transcriptional activities: Myc/Max dimers activate, while Max/Mad or Max/Mnt complexes repress transcription from this site in arti®cial promoters (Amati and Land, 1994; Blackwell et al., 1990; Gu et al., 1993; Kretzner et al., 1992; Laherty et al., 1997; Murre et al., 1989; Prendergast et al., 1991; Sommer et al., 1997) . The equilibria among the various dimers are mainly controlled through extra-cellular signal induced modi®cations in Myc or Mad expression levels, the Max concentration remaining constant. Mad genes expression is induced during cell dierentiation, while c-myc transcription is regulated by tyrosine kinase signalling and is rapidly turned on during the G1 phase of the cell cycle, upon-mitogenic stimulation; DNA binding of Myc/Max complexes can also be regulated by posttranslational modi®cation, e.g. Max phosphorylation Berberich and Cole, 1992; Henriksson and Luscher, 1996; Zu et al., 1997) .
Heterodimers with Max are the functionally active form of the Myc protein, which homodimerizes and binds DNA poorly (Amati et al., 1993; Blackwood and Eisenman, 1991; Blackwood et al., 1992; Littlewood and Evan, 1994) . Myc/Max complexes activate transcription of several genes containing the CACGTG site, such as the genes for the polyammine biosynthesis enzyme ornithine decarboxylase, prothymosine a, the elongation factor eIF4E, the embryonic marker ECA39, the helicase MrDb, the growth-related factor Rcl and two cell cycle regulators: the CDC25A phosphatase and the E2F transcription factor (BelloFernandez and Cleveland, 1992; Benvenisty et al., 1992; Eilers et al., 1991; Galaktionov et al., 1996; Grandori et al., 1996; Jones et al., 1996; Leone et al., 1997; Lewis et al., 1997; Sears et al., 1997) . Myc can also repress transcription of cell cycle regulators, like cyclin D1 and Myc itself, and of growth arrest genes, like gas1 Penn et al., 1990; Peukert et al., 1997; Philipp et al., 1994) . It is unclear which genes represent the physiologically relevant Myc targets.
The Myc family proteins c-Myc, L-Myc and N-Myc have a role in the genesis of a wide range of neoplasias, including lymphomas, neuroblastomas and small cell lung carcinomas (Cory and Adams, 1988; Lombardi et al., 1987; Weiss et al., 1997) . Myc/Max dimers control an important step in cell cycle progression in the G1/S and, possibly, the G2/M transition (Seth et al., 1993) . CyclinE/Cdk2 complexes represent a major target for G1/S transition regulation by Myc. The activity of Myc/Max dimers neutralizes the p27 cell cycle inhibitor, activating cyclinE/CDK2 complexes, and overcomes growth inhibition by the p16/Rb pathway; this suggests that bypassing the tumour suppressor function of this pathway may be an essential feature of Myc oncogenic potential (Alevizopoulos et al., 1997; Steiner et al., 1995; Vlach et al., 1996) . Oncogenic activation of myc genes occurs mainly through a deregulated expression that leads to a shift of the equilibria among dimers towards Myc/Max complexes . Interfering with Myc dimerization is therefore biologically relevant and it should be possible to direct the operation of the Max network by controlling the equilibria among dierent dimers.
In this study, we investigated molecular recognition of Myc protein bHLHZip domain. We identi®ed by molecular modelling the critical amino acid residues for Myc/Max protein-protein interaction and constructed a mutant Myc with altered dimerization speci®city, Omomyc, able to homodimerize and to eciently form complexes with wild type Myc. Omomyc expression in mammalian cells provided an alternative bHLHZip domain to the Max network and was able to interfere with Myc transactivation and growth control. This may constitute an initial step to obtain peptides of pharmacological interest which control Myc and Max dimerization.
Results
Four amino acids in the leucine zipper are critical for Myc dimerization speci®city Myc and Max proteins from dierent species share a signi®cant degree of sequence similarity in their bHLHZip domains (Littlewood and Evan, 1994) . To identify the amino acids that are most important for dimerization, we utilized the crystallographic data of the DNA bound Max homodimer (FerreÁ -D'AmareÁ et al., 1993) for building, by homology, model structures of a hypothetical Myc homodimer and a Myc/Max heterodimer ( Figure 1a ). The Max bHLHZip domain consists of two long a-helices, separated by a loop; the N-terminal a-helix is composed of the basic region and of helix 1 (H1), the second a-helix includes helix 2 (H2) and the leucine zipper. H1 and H2 of the two monomers form a parallel four-helix bundle, a protein fold shared by bHLHZip and bHLH proteins; the two basic regions project from the bundle and bind DNA in the major groove (Ellenberger et al., 1994; FerreÁ -D'AmareÁ et al., 1993) . The two leucine repeat portions form a parallel coiled coil that closely resembles the leucine zipper of the yeast transcription factor GCN4 (FerreÁ -D'AmareÁ et al., 1993) . We focused our attention on the H2Zip region as our previous work showed that the N-terminal a-helix (bH1) is not involved in the speci®city of dimerization, which is dictated by H2Zip only . The classical leucine zipper structure is characterized by the heptad repeat (abcdefg)n, where leucines usually occupy d and hydrophobic amino acids a position, and is mainly stabilized by hydrophobic interactions between amino acids in a and d position of the two helices ( Figure 1c) ; interhelical salt bridges between an e residue of one strand and the preceding g residue of the other strand may give a further contribution to the stability of the structure. However, a prevalence of hydrophobic residues in a position is not observed in Myc and Max zippers (Figure 1c ). The dimeric model structures were analysed by visual inspection and by the ESCHER docking procedure (Ausiello et al., 1997) , evaluating electrostatic interactions and surface complementarity, in order to identify the amino acids involved in recognition speci®city.
By comparing Myc dimer model structure and Max dimer crystallographic structure, three regions ( Figure  1 ) were identi®ed as an obstacle to Myc homodimerization, as they displayed major steric and electrostatic clashes. They correspond to four charged amino acids, two glutamates (E57, E64) and two arginines (R70, R71), located in the leucine zipper, the region of greater diversity between Myc and Max; all four correspond to amino acids involved in dimerization according to the Max dimer crystallographic data. Three of them (E57, E64 and R71) are located in a position, involved in interactions stabilizing the leucine zipper dimer; the corresponding positions in Max are occupied by asparagine, isoleucine and asparagine (N,I,N), respectively. In the-Max homodimer, moreover, glutamine and asparagine residues at positions 70 and 71 of the two monomers form a remarkably stable tetrad (QN/QN) of major importance for structure stabilization (FerreÁ -D'AmareÁ et al., 1993) . Consequently, the poor Myc homodimerization is explained by the disruption of this tetrad, since positions 70 and 71 in Myc are occupied by aminoacids (two arginines) with the same polarity, and by the presence of three charged residues (the two glutamate 57,64 and arginine 71) at three consecutive a positions, that destabilize the Zipper region. Four dierent Myc model structures, with mutations in these four aminoacids (mut1-mut4), were built and the stability of the corresponding homoand heterodimeric (with Max and wild type Myc) structures evaluated (Figure 1) .
In Myc-mut1 (E57N, E64I), the glutamates 57 and 64 were substituted with asparagine and isoleucine, as in the Max protein (Figure 1c ). In mut2 (R70Q, R71N) the two arginines 70 and 71 were substituted with the corresponding Max amino acids (glutamine and asparagine), reconstituting the Max tetrad. The analysis of mutant model structures indicated that Myc-mut1 was unlikely to be able to dimerize because of the presence of the highly unfavourable RR/RR tetrad, while mut2 displayed a much nicer shape and electrostatic complementarity, even if the two E residues in positions 56 and 57 still represent a potentially destabilizing tetrad. Myc-mut3 (E57N, E64I, R70Q, R71N) has all four amino acids (57, 64, 70 and 71) substituted with the Max ones. This mutant was predicted to homodimerize only weakly, due to an unfavourable shape complementarity of amino acids around position 57. Therefore a fourth mutant structure, named mut4 or Omomyc (E57T, E64I, R70Q, R71N), was modeled. In this mutant, MycE57 was substituted with a T, while the other three amino acids were substituted with the amino acids present in Max. The T substitution provided a better shape complementarity between the two monomers ( Figure  1d ). As mut2 (where only the Max tetrad is reconstituted) and mut4 (where all four amino acids were mutated) model structures appeared favourable for homodimerization, the corresponding mutations were generated by PCR mutagenesis of the myc bHLHZip domain and introduced in the pC135 expression vector. The mutated Myc domains are fused in frame to the DNA binding domain of l phage cI repressor, producing a chimerical repressor . Omomyc bHLHZip domains around the four residues 57, 64, 70 and 71. These four positions were mutated in the Myc domain in order to obtain Omomyc: three of the four residues were substituted with corresponding aminoacids in Max, while glutamate (E) 57 was substituted with threonine (T), that appeared to ®t better than asparagine the structural model
Omomyc homodimerizes as eciently as Max
Dimerization of Myc and Max bHLHZip domains was tested by the chimeric l repressor assay (Castagnoli et al., 1994; Hu et al., 1990; Marchetti et al., 1995) in bacteria transformed by the plasmids producing cIbHLHZip domain fusion proteins. Dimerization of fusion proteins allows the formation of functional repressor molecules, since dimerization is essential for stable DNA binding and repression activity of the cI protein. The repressor assays reported in Figure 2 speci®cally re¯ect the dimerization ability of the bHLHZip domains fused to the l repressor, because dierent domains were produced at the same level in bacteria ( Figure 2d ).
Repressor function was ®rst qualitatively assessed, by determining sensitivity to l phage infection of bacteria producing dierent chimeric proteins: dimerization of bHLHZip domains confers resistance to phage infection, by allowing formation of repressing cI dimers ( Figure 2a ). As the Myc bHLHZip domain is unable to dimerize eciently, bacteria transformed by the cI-Myc fusion expression plasmid (pC135Myc) were sensitive to phage infection; by contrast, cIMax, which eciently forms dimers, conferred on host bacteria complete resistance to l infection (Figure 2b ). The cI-Mycmut2 chimera did not dimerize, as it was unable to confer immunity to phage infection (data not shown). The cI-Mycmut4 (cI-Omomyc) chimera, instead, dimerized eciently because it behaved like Max, rendering bacteria immune to phage infection.
Chimeric repressor dimerization was then quantitated, by measuring repression of b-galactosidase activity in GC421 bacteria transformed by plasmids directing the synthesis of cI-bHLHZip fusion proteins; in the GC421 bacterial strain, the b-galactosidase gene is under control of lP R O R (right promoter ± operator of phage l) and is expressed constitutively. Dimerization of cI-bHLHZip fusion proteins causes repression of the reporter gene, thus inhibiting b-galactosidase activity. The cI-Mycmut2 chimera, carrying only two of the four amino acid substitutions present in Omomyc, was unable to aect enzymatic activity (Figure 2c ). This ®nding con®rmed that the two mutations at positions 70 and 71 were not sucient for homodimerization, which was obtained only when all four destabilizing amino acids were changed. As a matter of fact, Omomyc lowered b-galactosidase expression as efficiently as Max (Figure 2c ). The ®nding that Mycmut2, which full®lled the modelling criteria, was unable to dimerize, can be accounted for by the uncertainty of homology modelling procedures. It can be considered that, for a 50% identity for a known structure built from another known structure, the mean error in the modelled coordinates can be as large as 1.5 A Ê ngstrom, with considerably larger local errors (Chothia and Lesk, 1986; Sippl, 1993) . Since the human Myc bHLHZip domain shares only a 36% identity with Max aminoacid sequence, our modelled structures, overall, showed a good ®t with experimental data. Therefore, only Omomyc was further analysed.
Omomyc forms dimeric complexes with Myc and Max
Heterodimer formation by Omomyc was assayed indirectly, through the ability of Myc and Max to compete with repressing cI-Omomyc dimers as a consequence of the formation of heterodimeric complexes with Omomyc. To this purpose, we have utilized an expression vector derived from pC135 to direct the synthesis of bHLHZip domains fused to a cI domain defective in operator recognition, cI* (Longo et al., 1995; Marchetti et al., 1995) . We have then tested the ability of these constructions to relieve l Pr transcription repression by a compatible plasmid, derived from pACYC184 and containing an active cIOmomyc gene ( Figure 3a) . As pACYC184 is a low copy number plasmid, it drives a lower level of expression as compared to the high copy number plasmid pC135. Therefore, the b-galactosidase activity repression reported in Figure 3 , which is relative to bacteria transformed by pACYC Max or Omomyc, is about sevenfold lower than reported in Figure 2 , where the pC135 vector was employed. In GC421 cells cotransformed by pACYC184Omomyc and pC135 * Myc or pC135*Max, heterodimer formation was easily detected by an increase in b-galactosidase activity as compared to cells transformed by pACYC184Omomyc only. In fact, the formation of cI-Omomyc/cI*-Myc and cI-Omomyc/cI*-Max heterodimers, which cannot bind the phage operator and do not repress bgalactosidase, interfered with the formation of repressing Omomyc homodimers.
These results demonstrate that Omomyc can form heterodimers with Myc and with Max; its binding to Max, however, is not as strong as the binding between Myc and Max (Figure 3b , last two columns).
Omomyc binds the CACGTG E box with low anity and interferes with Myc/Max dimer formation
To determine whether Omomyc binds the consensus binding site for Myc/Max and Max/Max complexes, gel shift assays were performed using puri®ed Omomyc, Myc and Max GST-fusion proteins and the radiolabelled DP oligonucleotide, containing the E-box sequence CACGTG. A shift was observed with Omomyc-GST and its speci®city was established by competition with dierent E-boxes (Figure 4a ). DNA binding of Omomyc dimers was inecient as it was observed only with relatively high protein amounts (greater than 250 ng), about tenfold higher than those required to observe a shift with Max or with other bHLH protein dimers. We then compared DNA binding of Omomyc dimers, Max dimers and Omomyc /Myc or /Max heterodimers. DNA bound GST-Max run as a doublet in our hands (lanes 1 and 2) . Omomyc formed heterocomplexes with Max which bound DNA (Figure 4b , lanes 7 ± 10) with a high eciency, similar to Myc/Max dimers (lanes 3 ± 6) and considerably . Mobility shift assays with the DP probe were performed with dierent amounts of Myc, Max and Omomyc GST-fusion proteins. The locations of gel shifts corresponding to dierent dimers are indicated by arrows. Lanes 1 ± 10: a constant amount of Max (20 ng), in the presence of increasing amounts (20 ± 200 ng) of Myc or Omomyc (lanes 3 ± 6 and 7 ± 10, respectively), was incubated with the DP oligonucleotide. Max antiserum C124 was used in the supershift experiments (lanes 1, 6 and 10). In our hands, this antiserum caused both supershift (lanes 6 and 10) and DNA binding inhibition (lanes 1, 6 and 10). Although DNA binding inhibition only was observed in lane 1 in this particular case, the identity of the Max/Max complex has been con®rmed in several other independent experiments. Lanes 11 ± 13: DNA binding of Omomyc (400 ng, lane 11) and Omomyc/Myc complexes (200 ng each, lane 12; 400 ng each, lane 13) was measured. Lanes 14 ± 16: increasing amounts (100, 200, 400 ng) of Omomyc were incubated in the presence of constant amounts of Myc (100 ng) and Max (20 ng) proteins. Shifts corresponding to heterodimers have a dierent mobility with respect to homodimers. Myc/Max (lanes 3 ± 5) and Omomyc/Max dimers (lanes 7 ± 9) bind the E box more eciently than Omomyc/Myc dimers (lanes 12 and 13) higher than Omomyc dimers (lane 11). DNA binding anity of Omomyc/Myc heterodimers was instead very low, as we were unable to observe a speci®c shift even at relatively high protein concentration (lanes 12 ± 13). We ®nally tested the capacity of Omomyc to interfere with Myc/Max dimerization and DNA binding. In the presence of increasing amounts of Omomyc protein, DNA binding of Myc/Max complexes was decreased, in parallel with the appearance of DNA bound Omomyc/Max complexes (lanes 14 ± 16).
These results indicated that the Omomyc protein interferes with Myc/Max dimer formation and competes, as homodimer and as heterodimer with Max, for DNA binding on the same sites targeted by the various Max network dimers. Moreover, they suggest that Omomyc can bind Myc and sequester it into complexes inactive in DNA binding and, consequently, in transcriptional activation.
Omomyc interferes with Myc induced transactivation
The ability of Omomyc to interfere with dimerization and DNA binding of Myc/Max complexes suggested that it might aect transcriptional regulation by Myc/ Max dimers in mammalian cells.
To establish the potential of Omomyc to aect transcriptional regulation by Myc/Max complexes, BOSC23 cells were transfected with expression vectors and the plasmid M4minCAT, containing the CAT reporter gene linked to a minimal thymidine kinase promoter with four repeats of the CACGTG E box. CAT activity of the reporter was increased about fourfold by a cotransfected Myc expression plasmid, compared with control vector (Figure 5 ). Omomyc caused instead a 50% repression of the basal level of CAT activity and a signi®cant inhibition of transcriptional activation by Myc. This eect was dependent on the E box as no repression or activation was observed with the minCAT reporter, devoid of the E boxes (data not shown). As Myc transactivation depends on the formation of Myc/Max complexes, this result might be explained by Omomyc inhibition of both Myc and the endogenous Max protein, present in relatively large amounts. To distinguish between the two possible eects of Omomyc, we performed transfections with a vector expressing a truncated Myc protein (DMyc), containing the bHLHZip domain only. DMyc is unable to transactivate, because it lacks the Myc activation domain, and dimerizes with Max, but not with Myc. This protein neither repressed CAT activity or inhibited Myc mediated transactivation (Figure 5 ), suggesting that, although Omomyc can bind Myc and Max equally well (Figure 4 ), transcriptional repression is mainly due to Myc inhibition. This was further con®rmed by the ®nding that repression of CAT activity by Omomyc was reversed by an excess of Myc protein ( Figure 5 , last column).
Omomyc inhibits cell proliferation in mammalian cells
Since the Myc protein is required for cell cycle progression, the ability of Omomyc to aect cell proliferation was tested, by a colony formation assay in NIH3T3 cells. These cells were transfected with Omomyc and Myc expression vectors together with a neomycin resistance plasmid; number and size of neomycin resistant colonies were scored 2 weeks later ( Figure 6 ). Myc expression plasmid did not aect colony formation, whereas Omomyc caused a *tenfold reduction in colony number; the Omomyc colonies were on the average one third the diameter of those obtained with Myc expression or empty vectors. This eect is Myc dependent, at least in part, since DMyc, which does not interact with Myc, aected colony formation in an intermediate way between Myc and Omomyc and since Myc overexpression rescued the proliferation arrest caused by Omomyc. These data strongly suggest that Omomyc aects cell proliferation by interfering with transcriptional regulation of Myc/ Max target genes.
Discussion
The basic cellular processes of proliferation, differentiation and death, are controlled by complex regulatory pathways triggered by extracellular signals and converging to regulation of gene expression. In this context, bHLH(Zip) transcriptional regulators (MyoD, Achaete-Scute, Mash, NeuroD, E2A, Myc, Max etc) are often utilized as a crucial switch, for instance in muscle cells and in cells of the nervous and immune systems. Our aim was to understand the rules underlying protein-protein recognition in this class of proteins in order to develop tools for interfering with such transcription regulatory networks. The signal transduction pathways that have an impact on transcription factors networks are intricate as well as branched. Therefore, it proves to be dicult controlling these networks from the outside, e.g. by acting on the extracellular signal, their receptors or on a component of the transduction machinery, such as the Ras protein. Therefore we have decided to follow a dierent strategy, that consists in the design, by molecular modelling, of a new protein domain which acts from within, by altering the balance among dierent factors of one of these networks, the Max network. Naturally occurring dominant negative mutations in bHLHZip proteins, like those in the Mi gene (Moore, 1995) , as well as previously designed dominant mutations (Krylov et al., 1997) aect the function of the basic region, thus abolishing DNA binding. Our target was instead protein dimerization. Myc/Max dimers are key players of the Max network. Previous works (Amati et al., 1993; Marchetti et al., 1995; Muhle-Goll et al., 1995) showed the importance of the zipper region for Myc dimerization speci®city; the Myc HLHZip exchange mutant MycRX, a Myc containing the HLHZip domain of Max, was shown to have a dominant negative activity on wild type Myc function (Amati et al., 1993) . The present work represents a further advancement for two reasons: (i) We were able to identify four amino acids (E57, E64, R70, R71) that, when mutated, modify Myc molecular recognition; (ii) These critical residues are all included in a region of only 14 amino acids within the leucine zipper and two of them (E57 and R70) are conserved among all members of the Myc protein family (c-Myc, v-Myc, N-Myc, S-Myc, L-Myc, d-Myc; Table 1 ). This implies that this small region may represent a less complex structural target for Myc activity inhibition. Myc E57 and E64 are thought to be involved in interhelical electrostatic interactions, together with Max H60, responsible for heterodimerization specificity (Lavigne et al., 1995) . Our data are only partly consistent with this model, as substitution of the two negatively charged glutamic residues with a polar and a nonpolar aminoacid (T and I) aected Myc heterodimerization with Max only weakly (Figure 3b ), while it turned out to be essential for Myc homodimerization. By substituting the four amino acids we obtained a new bHLHZip domain, Omomyc, that homodimerized as strongly as Max and eciently formed heterodimers with wild type Myc, as well as with Max.
Since the proteins in the Max network act on a speci®c DNA target site (the CACGTG E box), we tested the ability of Omomyc to compete with other network dimers for binding to this site; speci®c binding of this protein to the E box was demonstrated. Two Myc basic regions (present in Omomyc/Omomyc and Omomyc/Myc dimers) were inecient in binding to the E box (Figure 4 ), pointing to a speci®c role of the Max basic region in target site recognition (see also Amati et al., 1993) . DNA binding of the Omomyc/Max dimer was instead observed at lower protein concentration, but these dimers, which lack any transactivating region, are transcriptionally inactive. On the basis of these observations we predicted that Omomyc expression in mammalian cells should result in a dominant phenotype as a consequence of interference with Myc physiological functions: transcriptional regulation and cell growth control. Transient transfections demonstrated that Omomyc aects transcription of a promoter containing the E box CACGTG and inhibits Myc transactivating capacity in a dose dependent manner. These eects are mainly due to complex formation with Myc, rather than to sequestration of Max. This is shown by the inability of the DMyc protein, unable to bind Myc while still interacting with Max, to have a comparable eect and by the ®nding that Myc overexpression overcomes the transcriptional inhibition exherted by Omomyc. Finally, and coherently with the results of the transactivation assays, Omomyc was able to arrest cell proliferation in a colony formation assay in NIH3T3 ®broblasts. The distinctive dimerization property of Omomyc is a tool to better dissect Myc mechanism of action in cell cycle control. Furthermore our results support the view that sequestration of endogenous Myc is an eective strategy to control cell proliferation.
This encourages us to utilize Omomyc or a Omomyc-like peptide for interfering with the most relevant biological aspect of Myc protein function: cell transformation. To this end, retroviral or adenoviral vectors can be exploited for peptide delivery inside the cell. Alternatively, shorter peptides with Omomyc-like properties could be designed and delivered to the cytoplasm of Myc dependent tumor cells by fusion to an Antennapedia homeodomain. Finally these shorter peptides could be used as leads for the design of smaller peptide-mimetics with better pharmacological properties.
The results that we have obtained with Omomyc prove the validity of the strategy we adopted and open the way to the design of other mutants, displaying an increased selectivity in their interaction with Myc.
Materials and methods

Molecular modelling
Model structures of human Max, Myc and mutant Myc bHLHZip domain homo-and heterodimers were built by homology using the Max dimer three-dimensional crystal structure (FerreÁ -D'AmareÁ et al., 1993) as a template. Modelling was carried out on a Silicon Graphics O2 workstation R5000SC, using the Insight II program. Models were subjected to 100 cycles of energy re®nement (Discover program, steepest descent algorithm, Biosym Technologies). Stability of dimeric structures was evaluated by the ESCHER automatic procedure (Ausiello et al., 1997) and by visual inspection.
Plasmids, mutagenesis and protein expression pC135Myc and pC135Max plasmids, containing the bHLHZip domains of human myc (amino acid residues 348 ± 439) and max (aminoacids 11 ± 99) genes were already described . pC135Myc was used as a template for PCR mutagenesis, by the Stratagene QuikChange site directed mutagenesis kit, primed by speci®c oligonucleotides containing the desired mutations. The following oligonucleotides were used for R70Q and R71N substitutions (Myc-mut2): 5'-GTT GCG GAA ACA AAA CGA ACA GTT GA-3' and 5'-TCA ACT GTT CGT TTT GTT TCC GCA AC-3'. pC135Myc-mut2 was then used as a template for a second mutagenesis round, primed by the following oligonucleotides introducing E57N and E64I substitutions: 5'-CAA GCA GAG ACG CAA AAG CTC ATT TCT GAA ATC GAC TTG TTG-3' and 5'-CAA CAA GTC GAT TTC AGA AAT GAG CTT TTG CGT CTC-3'. The plasmid containing the Myc mutant with the four substitutions was called pC135-Omomyc (Mycmut4). The bHLHZip domains in all these constructs are fused in frame with lambda phage cI repressor Nterminal domain (aminoacids 1 ± 132) at the 5' end and the b-galactosidase a-peptide gene at the 3' end; their expression is driven by the lac promoter. All constructs were sequenced by the Sanger method to con®rm the mutations identity and the proper reading frame. pC135* is similar to pC135, but has three mutations that replace three residues in the l repressor DNA binding domain with the corresponding amino acids of the 434 phage repressor (Longo et al., 1995; Marchetti et al., 1995) . pACYCbHLHZip plasmids were constructed by replacing the 1690 bp HindII-HindIII fragment of pACYC184 (Chang and Cohen, 1978) with PvuII-PvuII fragments (containing the Plac-cI-bHLHZ-a-peptide fusions) excised from pC135-bHLHZip plasmids. The chimerical plasmids were introduced by electroporation into Sure cells (from Stratagene), which were selected in ampicillin and/or chloramphenicol supplemented medium. The GST (glutathione-S-transferase)-Omomyc fusion was constructed in the pGEX-2TK vector (Pharmacia). The Omomyc DNA sequence was ampli®ed from pC135Omomyc by polymerase chain reaction (PCR) primed by the following oligonucleotides: 5'GGA GAG CCC GGG GTC GAC CGA GGA GAA3', containing a SmaI site, and 5'ATG TCA ATC ATA TGT ACC CCG GTT3', located downstream of the coding sequence. The omomyc gene was excised as a SmaI-EcoRI fragment and cloned in the pGEX-2TK vector, in frame with the C terminus of GST.
For the detection of cI-bHLHZip proteins, bacterial cells transformed with dierent expression vectors were lysed in sample buer; the extracts were used in immunoblotting, probed with Max (C-124) and Myc (237/6) speci®c antisera.
Chimeric repressor dimerization assays
Phage Immunity Test l phage sensitivity of bacterial cells transformed by pC135bHLHZip plasmids was tested by spot tests, at concentrations varying from 10 5 to 10 1 phages (lDHK54) per spot on lawns of transformed bacteria.
b-galactosidase assay For a quantitative assay of chimeric repressor dimerization, the pC135bHLHZip plasmids were introduced into the GC421 strain, which constitutively expresses b-galactosidase under the control of lPrOr (right promoter-operator). Chimerical repressors dimerization was measured by % inhibition of b-galactosidase activity in trasformed bacteria with respect to b-galactosidase activity in non trasformed ones, after bacterial lysis as described Miller et al., 1972) .
Heterodimerization Assay Heterodimerization ability was estimated by the increase of b-galactosidase activity in GC421 cells co-trasformed with pACYCbHLHZip and pC135*bHLHZip, with respect to the inhibition obtained in cells transformed with pACYCbHLHZip only.
Electrophoretic mobility shift assays (EMSA)
GST-bHLHZip fusion proteins were anity-puri®ed on glutathione-agarose beads and then eluted with reduced glutathione; amounts of puri®ed GST fusion proteins were used in DNA binding assays. A 30 min incubation at 378C was performed to allow dimers exchange; speci®c (DP) and non-speci®c (ZT, VZ) competitor oligonucleotides were added and a further 15 min incubation at room temperature was performed to allow the DNA-protein complex to form. One ml of anti-Max antiserum (C124, from Santa Cruz) was added to the reaction mixture for the supershift experiments. 10 4 c.p.m. of 32 P end-labelled double-stranded DP oligonucleotide was used per reaction; speci®c and non speci®c competitors were added at a 100-fold excess. The DP oligonucleotide (5'-CGGGGCGAGACCACGTGAC-CCCGC-3', Marchetti et al., 1995) includes the CACGTG E box. In ZT and VZ oligonucleotides the E box sequence CACGTG is replaced respectively by the sequences CAGGTT and CATTTG.
CAT assays
For the construction of expression vectors, Omomyc and DMyc (Myc bHLHZip domain) sequences were ampli®ed by PCR with Pfu polymerase, primed by oligonucleotides providing an ATG and a ribosome binding site, and inserted downstream of the CMV promoter in the pCS+ plasmid (from D Turner); the Myc expression vector was pBabe-neo-c/vMyc (Crouch et al., 1990) . BOSC23 cells were transfected with calcium phosphate (3610 5 cells in a 35 mm dish and 5 mg DNA per experiment). One mg of the chloramphenicol acetyltransferase (CAT) reporter plasmid M4minCAT (from R Eisenman) was co-transfected with 0.3 mg of pRSVb-gal in order to assess transfection eciencies; total amount of transfected DNA was balanced in all experiments by empty pCS plasmid. CAT activity was assayed by the diusion method of Neuman et al. (1987) ; CAT values were corrected for transfection eciency by normalization to b-galactosidase values. All assays were performed at least three times; average values and standard deviations are reported.
Colony Forming Eciency (CFE) assays
NIH3T3 cells were transfected with calcium phosphate (2610 6 cells in a 10 cm dish and 15 mg DNA per experiment). The expression vectors were co-transfected with the neomycin resistance plasmid pSV2neo (3 mg). For each individual experiment, cells were split into at least triplicate dishes (1/4, 1/8, 1/16 dilutions) 18 ± 24 h posttransfection. After 48 h, 800 mg/ml G418 was added. Two weeks later, colonies were ®xed in methanol and stained with Giemsa.
